应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01099 国药控股
交易中 08-28 10:41:12
17.640
-0.100
-0.56%
最高
17.800
最低
17.540
成交量
174.25万
今开
17.720
昨收
17.740
日振幅
1.47%
总市值
550.48亿
流通市值
236.70亿
总股本
31.21亿
成交额
3,070万
换手率
0.13%
流通股本
13.42亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
南向资金8月27日净卖出国药控股20.12万股 连续5日减持
市场透视 · 09:30
南向资金8月27日净卖出国药控股20.12万股 连续5日减持
国药控股(01099.HK)选举赵炳祥任董事长
阿斯达克财经 · 09:16
国药控股(01099.HK)选举赵炳祥任董事长
国药控股(01099.HK)拟委任连万勇为执行董事
格隆汇 · 08-27 21:13
国药控股(01099.HK)拟委任连万勇为执行董事
国药控股(01099)建议委任赵炳祥为非执行董事
智通财经 · 08-27 21:09
国药控股(01099)建议委任赵炳祥为非执行董事
异动解读 | 国药控股中期业绩低迷 盘中大跌5.28%
异动解读 · 08-27 16:24
异动解读 | 国药控股中期业绩低迷 盘中大跌5.28%
异动解读 | 国药控股上半年营收利润均出现下滑 股价应声下挫
异动解读 · 08-27 16:24
异动解读 | 国药控股上半年营收利润均出现下滑 股价应声下挫
野村:予国药控股(01099)“买入”评级 目标价30.33港元
智通财经 · 08-27 15:23
野村:予国药控股(01099)“买入”评级 目标价30.33港元
大摩:维持国药控股(01099)“增持”评级 目标价降至25港元
智通财经 · 08-27 14:52
大摩:维持国药控股(01099)“增持”评级 目标价降至25港元
《大行》中金降国药(01099.HK)目标价至24.7元 中期业绩符预期
阿斯达克财经 · 08-27 13:57
《大行》中金降国药(01099.HK)目标价至24.7元 中期业绩符预期
花旗:予国药控股(01099)“买入”评级 目标价下调至26港元
智通财经 · 08-27 11:11
花旗:予国药控股(01099)“买入”评级 目标价下调至26港元
港股异动 | 国药控股(01099)续跌4% 上半年营收净利双降 机构下调公司盈测及目标价
智通财经网 · 08-27 11:07
港股异动 | 国药控股(01099)续跌4% 上半年营收净利双降 机构下调公司盈测及目标价
大行评级|花旗:下调国药控股目标价至26港元 下调2024至26年每股盈测
格隆汇 · 08-27 10:42
大行评级|花旗:下调国药控股目标价至26港元 下调2024至26年每股盈测
《大行》大摩降国药(01099.HK)目标价至25元 下调每股盈测
阿斯达克财经 · 08-27 10:16
《大行》大摩降国药(01099.HK)目标价至25元 下调每股盈测
国药控股(01099.HK):1H24业绩符合预期 财务费用同比下降
中金公司 · 08-27 08:15
国药控股(01099.HK):1H24业绩符合预期 财务费用同比下降
国药控股08月26日获主力加仓278万元 环比增加612.82%
市场透视 · 08-26 16:16
国药控股08月26日获主力加仓278万元 环比增加612.82%
港股异动 | 国药控股(01099)现跌超5% 器械分销及医药零售业务收入下降 中期纯利、营收均同比下滑
智通财经 · 08-26 10:43
港股异动 | 国药控股(01099)现跌超5% 器械分销及医药零售业务收入下降 中期纯利、营收均同比下滑
【国药控股:审计机构变更为天健会计师事务所】金十数据8月26日讯,国药控股股份有限公司公告,审计机构由普华永道中天会计师事务所(特殊普通合伙)变更为天健会计师事务所(特殊普通合伙)。
美港电讯 · 08-26 09:48
【国药控股:审计机构变更为天健会计师事务所】金十数据8月26日讯,国药控股股份有限公司公告,审计机构由普华永道中天会计师事务所(特殊普通合伙)变更为天健会计师事务所(特殊普通合伙)。
【港股通】国药控股(01099)绩后跌4.85% 中期溢利、营收均同比下滑
金吾资讯 · 08-26 09:44
【港股通】国药控股(01099)绩后跌4.85% 中期溢利、营收均同比下滑
国药(01099.HK)绩后跌逾6% 半年少赚一成
阿斯达克财经 · 08-26 09:34
国药(01099.HK)绩后跌逾6% 半年少赚一成
国药控股盘中异动 股价大跌5.06%报17.620港元
市场透视 · 08-26 09:31
国药控股盘中异动 股价大跌5.06%报17.620港元
公司概况
公司名称:
国药控股
所属市场:
SEHK
上市日期:
--
主营业务:
国药控股股份有限公司是一家主要从事药品及医疗器械分销业务的中国公司。该公司通过四个部门运营业务。医药分销部门向医院、其他分销商、零售药店及诊所等客户分销医药制品。医疗器械业务部门向客户分销医疗器械,并提供安装和维修服务。医药零售业务部门经营医药连锁店。其他业务部门分销实验室用品、制造及分销化学试剂、生产及销售医药制品。
发行价格:
--
{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":17.64,"timestamp":1724812845600,"preClose":17.74,"halted":0,"volume":1742522,"delay":0,"floatShares":1341810740,"shares":3120656191,"eps":3.1779585,"marketStatus":"交易中","marketStatusCode":2,"change":-0.1,"latestTime":"08-28 10:41:12","open":17.72,"high":17.8,"low":17.54,"amount":30700406,"amplitude":0.014656,"askPrice":17.66,"askSize":26000,"bidPrice":17.64,"bidSize":3600,"shortable":3,"etf":0,"ttmEps":3.1835753701378224,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1724817600000},"adr":0,"listingDate":1253635200000,"adjPreClose":17.74,"dividendRate":0.05405,"openAndCloseTimeList":[[1724808600000,1724817600000],[1724821200000,1724832000000]],"volumeRatio":0.963118,"impliedVol":0.337,"impliedVolPercentile":0.0726,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK"},"requestUrl":"/m/hq/s/01099/wiki","defaultTab":"wiki","newsList":[{"id":"2462176433","title":"南向资金8月27日净卖出国药控股20.12万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2462176433","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462176433?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:30","pubTimestamp":1724808608,"startTime":"0","endTime":"0","summary":"8月27日,南向资金减持国药控股20.12万股连续5日减持。截止当日收盘,港股通共持有国药控股22886.33万股,占流通股17.05%。国药控股近5个交易日下跌9.49%,港股通累计减持618.80万股;近20个交易日下跌0.56%,港股通累计减持295.67万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408280931249f5ff19b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408280931249f5ff19b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU1115378108.SGD","LU0640798160.USD","BK1515","BK1197","01099"],"gpt_icon":0},{"id":"2462517349","title":"国药控股(01099.HK)选举赵炳祥任董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2462517349","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462517349?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:16","pubTimestamp":1724807760,"startTime":"0","endTime":"0","summary":"两人将由中国医药集团另有任用。董事会于同日决议选举赵炳祥担任董事会董事长。任职须待股东于公司股东特别大会上批准其非执行董事的委任后方可生效。董事会亦决议建议委任赵炳祥为非执行董事,及建议委任连万勇为执行董事。(港股报价延迟最少十五分钟。沽空资料截至 2024-08-27 16:25。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240710142001125_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240710142001125_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1375996/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1500","BK1197","LU0640798160.USD","01099","BK1515","LU1115378108.SGD"],"gpt_icon":0},{"id":"2462198646","title":"国药控股(01099.HK)拟委任连万勇为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2462198646","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462198646?lang=zh_cn&edition=full","pubTime":"2024-08-27 21:13","pubTimestamp":1724764410,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨国药控股公告,于2024年8月27日,董事会决议建议委任赵炳祥为非执行董事,及建议委任连万勇为执行董事。【免责声明】本文仅代表作者本人观点,与和讯网无关。和讯网站对文中陈述、观点判断保持中立,不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考,并请自行承担全部责任。邮箱:news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082721203395c95528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082721203395c95528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099","LU1115378108.SGD","BK1500","BK1515","BK1197","LU0640798160.USD"],"gpt_icon":0},{"id":"2462160249","title":"国药控股(01099)建议委任赵炳祥为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2462160249","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462160249?lang=zh_cn&edition=full","pubTime":"2024-08-27 21:09","pubTimestamp":1724764141,"startTime":"0","endTime":"0","summary":"智通财经APP讯,国药控股 发布公告,于2024年8月27 日,董事会决议建议委任赵炳祥为非执行董事,及建议委任连万勇为执行董事。于2024年8月27日,董事会决议选举赵炳祥担任董事会董事长。赵作为董事会董事长的任职须待股东于公司股东特别大会上批准其非执行董事的委任后方可生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1172342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0640798160.USD","01099","LU1115378108.SGD","BK1515","BK1197","BK1500"],"gpt_icon":0},{"id":"1136296759","title":"异动解读 | 国药控股中期业绩低迷 盘中大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136296759","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136296759?lang=zh_cn&edition=full","pubTime":"2024-08-27 16:24","pubTimestamp":1724747078,"startTime":"0","endTime":"0","summary":"国药控股今日盘中大幅下跌5.28%,引发市场关注。公司今早公布中期业绩显示,上半年净利润同比下降9.76%至37.04亿元人民币,每股基本盈利1.19元,而且不派发中期股息。导致上半年业绩不佳的主要原因是公司营收同比下跌2.07%至2947.27亿元人民币。同时,国药控股上半年毛利率下降0.28个百分点至7.45%,经营利润率下滑0.39个百分点至2.79%,利润率水平有所下降。此外,公司还宣布将委任天健国际会计师事务所及天健会计师事务所接替普华永道,担任2024年度国际和国内核数师。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"gpt_icon":0},{"id":"1131746398","title":"异动解读 | 国药控股上半年营收利润均出现下滑 股价应声下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1131746398","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131746398?lang=zh_cn&edition=full","pubTime":"2024-08-27 16:24","pubTimestamp":1724747044,"startTime":"0","endTime":"0","summary":"$国药控股(01099)$8月26日公布了2024年上半年财报,业绩出现一定程度下滑。报告显示:\n\n上半年,国药控股实现营收2947.27亿元人民币,较去年同期下降2.07%。其中医药分销业务仍保持相对稳健,但器械分销和医药零售业务收入则出现不同程度下滑。\n\n国药控股上半年的毛利率为7.45%,同比减少0.28个百分点。净利润为37.04亿元,大减9.76%,每股收益为1.19元。公司决定不派发中期股息。\n\n除业绩下滑外,国药控股还宣布将聘请天健事务所接替普华永道,成为公司2024年度的国内外核数师。该决定或引发投资者关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"gpt_icon":0},{"id":"2462139087","title":"野村:予国药控股(01099)“买入”评级 目标价30.33港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462139087","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462139087?lang=zh_cn&edition=full","pubTime":"2024-08-27 15:23","pubTimestamp":1724743436,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,野村发布研究报告称,予国药控股(01099)“买入”评级,目标价为30.33港元。公司2024年上半年收入为2947亿元人民币(下同),同比减2.1%,第二季销售额同比下降5.1%至1473亿元,比该行的预测低5.6%。第二季毛利率小幅下降0.2个百分点至7.8%,与该行的预期一致。该行认为,国药业绩回落主要是由于不利的销售组合变化和2023年上半年的高基数。由于市场推广及行政费用率上升,经营溢利率为3.4%,同比减0.4个百分点,比该行的预测低0.2个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1171513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099"],"gpt_icon":0},{"id":"2462135980","title":"大摩:维持国药控股(01099)“增持”评级 目标价降至25港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462135980","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462135980?lang=zh_cn&edition=full","pubTime":"2024-08-27 14:52","pubTimestamp":1724741550,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,摩根士丹利发布研究报告称,国药控股(01099)公布上半年业绩后,由于营收和毛利率较低,将2024至2030年的盈利预测下调3至9%。该行将对国药的目标价和情境值下调7%至8%,目标价由27港元降至25港元,维持“增持”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1171497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099"],"gpt_icon":0},{"id":"2462214187","title":"《大行》中金降国药(01099.HK)目标价至24.7元 中期业绩符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2462214187","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462214187?lang=zh_cn&edition=full","pubTime":"2024-08-27 13:57","pubTimestamp":1724738220,"startTime":"0","endTime":"0","summary":"中金发表报告指,国药上半年营业收入2,947.27亿元人民币,按年跌2.07%;归母净利润37.04亿元人民币,按年跌9.76%,对应每股收益1.19元人民币,符合预期。中金表示,分销业务持续增长,上半年分销收入按年增长0.47%至2,264.94亿元人民币;分销分部的经营利润率为2.75%,按年跌0.21个百分点。该行表示,考虑到公司零售和器械分销业务受政策影响,分别将公司今年及明年每股盈测下调至2.9元及3.1元,按年增长1%及6%,并将国药目标价下调5%至24.7元,其评级为“跑赢行业”。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220907154104342_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220907154104342_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1375650/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01099"],"gpt_icon":0},{"id":"2462745907","title":"花旗:予国药控股(01099)“买入”评级 目标价下调至26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462745907","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462745907?lang=zh_cn&edition=full","pubTime":"2024-08-27 11:11","pubTimestamp":1724728308,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,花旗发布研究报告称,降国药控股(01099)2024至2026年各年每股盈测分别12%、12%及12%,以反映最新收入增长放缓及利润率趋势,对国药目标价由30港元下调至26港元,评级“买入”。在上半年业绩电话会议中,管理层指出7月份营收开始复苏,并录得同比增长,预期复苏势头将于下半年持续,下半年毛利率料较上半年有所改善。上半年公司财务费用比率下降11个基点至0.36%。管理层预期,在低利率环境下,下半年财务费用率将会降低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1171424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099"],"gpt_icon":0},{"id":"2462022229","title":"港股异动 | 国药控股(01099)续跌4% 上半年营收净利双降 机构下调公司盈测及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2462022229","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462022229?lang=zh_cn&edition=full","pubTime":"2024-08-27 11:07","pubTimestamp":1724728025,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国药控股续跌4%,截至发稿,跌3.76%,报17.42港元,成交额8509.64万港元。消息面上,国药控股近日发布截至2024年6月30日止6个月业绩,收入2.95亿元,同比减少2.07%;母公司拥有者应占溢利370.39万元,同比减少9.76%。今年上半年,公司毛利率为7.45%,同比减少0.28个百分点,主要由于高毛业务占比略微下降。摩根士丹利研报指出,国药公布上半年业绩后,由于营收和毛利率较低,将2024至2030年的盈利预测下调3至9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408271111169f5ceb61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408271111169f5ceb61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099"],"gpt_icon":0},{"id":"2462904439","title":"大行评级|花旗:下调国药控股目标价至26港元 下调2024至26年每股盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2462904439","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462904439?lang=zh_cn&edition=full","pubTime":"2024-08-27 10:42","pubTimestamp":1724726539,"startTime":"0","endTime":"0","summary":"花旗发表报告指,国药控股在上半年业绩电话会议中,管理层指出7月份营收开始复苏,并录得按年增长,预期复苏势头将于下半年持续,下半年毛利率料较上半年有所改善。上半年公司财务费用比率下降11个基点至0.36%。管理层预期,在低利率环境下,下半年财务费用率将会降低。该行降国药2024至2026年各年每股盈测分别12%、12%及12%,以反映最新收入增长放缓及利润率趋势,对国药目标价由30港元降至26港元,评级“买入”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240827104219ab5fefe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240827104219ab5fefe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099"],"gpt_icon":0},{"id":"2462016999","title":"《大行》大摩降国药(01099.HK)目标价至25元 下调每股盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2462016999","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462016999?lang=zh_cn&edition=full","pubTime":"2024-08-27 10:16","pubTimestamp":1724724960,"startTime":"0","endTime":"0","summary":"摩根士丹利发表报告指,国药(01099.HK) 公布上半年业绩后,由于营收和毛利率较低,将2024至2030年的盈利预测下调3至9%。该行将对国药的目标价和情境值下调7%至8%,目标价由27元降至25元,此相当于今年市盈率8.1倍,维持“增持”评级。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-26 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220907154102451_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220907154102451_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1375573/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01099"],"gpt_icon":0},{"id":"2462974966","title":"国药控股(01099.HK):1H24业绩符合预期 财务费用同比下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2462974966","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462974966?lang=zh_cn&edition=full","pubTime":"2024-08-27 08:15","pubTimestamp":1724717724,"startTime":"0","endTime":"0","summary":"1H24 业绩符合我们预期公司公布1H24 业绩:营业收入2,947.27 亿元人民币,同比-2.07%;归母净利润37.04 亿元,同比-9.76%,对应每股收益1.19 元,符合我们的预期。根据公司公告,2024 年上半年,公司分销收入同比增长0.47%至2,264.94 亿元人民币;分销分部的经营利润率为2.75%,同比-0.21 个百分点。毛利率与财务费用率同比下降。风险药品集中采购压力,医药零售及医疗器械分销业务增长不及预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082708152895c743c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082708152895c743c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1115378108.SGD","01099","BK1500","BK1515","BK1197","LU0640798160.USD"],"gpt_icon":0},{"id":"2462978968","title":"国药控股08月26日获主力加仓278万元 环比增加612.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462978968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462978968?lang=zh_cn&edition=full","pubTime":"2024-08-26 16:16","pubTimestamp":1724660160,"startTime":"0","endTime":"0","summary":"08月26日, 国药控股股价跌2.48%,报收18.10元,成交金额2.08亿元,换手率0.87%,振幅6.79%,量比2.33。国药控股今日主力资金净流入278万元,连续6日净流入,上一交易日主力净流入39万元,今日环比增加612.82%。近一年数据显示,该股主力连续6日净流入后,次日上涨概率为37.50%,平均涨幅为1.88%。该股近5个交易日下跌7.24%,主力资金累计净流入1690万元;近20日主力资金累计净流出1425万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408261616499f59e0f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408261616499f59e0f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1197","LU1115378108.SGD","BK1500","LU0640798160.USD","01099","BK1515"],"gpt_icon":0},{"id":"2462498009","title":"港股异动 | 国药控股(01099)现跌超5% 器械分销及医药零售业务收入下降 中期纯利、营收均同比下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2462498009","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462498009?lang=zh_cn&edition=full","pubTime":"2024-08-26 10:43","pubTimestamp":1724640182,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国药控股现跌超5%,截至发稿,跌5.17%,报17.6港元,成交额9851.23万港元。消息面上,国药控股发布截至2024年6月30日止6个月业绩,该集团期内取得收入2.95亿元人民币,同比减少2.07%;母公司拥有者应占溢利370.39万元,同比减少9.76%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1170303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","159938","09939"],"gpt_icon":0},{"id":"2462845079","title":"【国药控股:审计机构变更为天健会计师事务所】金十数据8月26日讯,国药控股股份有限公司公告,审计机构由普华永道中天会计师事务所(特殊普通合伙)变更为天健会计师事务所(特殊普通合伙)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2462845079","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462845079?lang=zh_cn&edition=full","pubTime":"2024-08-26 09:48","pubTimestamp":1724636914,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1515","BK1197","LU0640798160.USD","01099","LU1115378108.SGD","BK1500"],"gpt_icon":0},{"id":"2462982100","title":"【港股通】国药控股(01099)绩后跌4.85% 中期溢利、营收均同比下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2462982100","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462982100?lang=zh_cn&edition=full","pubTime":"2024-08-26 09:44","pubTimestamp":1724636682,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国药控股 绩后股价下行,截至发稿,跌4.85%,报17.66港元,成交额4404.93万港元。期内,收入2947.27亿元,同比减少2.07%;毛利录得219.43亿元,同比减少5.7%。器械分销业务则受到终端需求结构变化的影响,实现销售收入584.94亿元,同比下降7.08% ,收入占比为19.14% ,较上年同期下降1.07个百分点。医药零售业务收入为165.58亿元,同比下降6.43% ,收入占比为5.42% ,较上年同期微降0.26个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408261004559f584acd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408261004559f584acd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099","HSCEI","HSTECH","07226"],"gpt_icon":0},{"id":"2462849409","title":"国药(01099.HK)绩后跌逾6% 半年少赚一成","url":"https://stock-news.laohu8.com/highlight/detail?id=2462849409","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462849409?lang=zh_cn&edition=full","pubTime":"2024-08-26 09:34","pubTimestamp":1724636040,"startTime":"0","endTime":"0","summary":"国药控股(01099.HK) 今日(26日)平开后掉头下跌,现报17.36元,跌6.47%,成交47.32万股,涉资850.88万元。国药上半年盈利按年跌9.8%至37.04亿元人民币,收入跌2.1%至2,947.27亿元人民币,主要受累于医药零售业务及器械分销业务收入下降所致。(mn/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-23 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220907154102451_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220907154102451_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1374912/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0640798160.USD","BK1515","01099","BK1197","BK1500","LU1115378108.SGD"],"gpt_icon":0},{"id":"2462984484","title":"国药控股盘中异动 股价大跌5.06%报17.620港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462984484","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462984484?lang=zh_cn&edition=full","pubTime":"2024-08-26 09:31","pubTimestamp":1724635880,"startTime":"0","endTime":"0","summary":"2024年08月26日早盘09时31分,国药控股股票出现波动,股价大幅下挫5.06%。截至发稿,该股报17.620港元/股,成交量37.52万股,换手率0.03%,振幅5.06%。资金方面,该股资金流入182.738万港元,流出447.094万港元。国药控股股票所在的药品分销行业中,整体涨幅为0.00%。其相关个股中,思派健康、叮当健康、京东健康涨幅较大,振幅较大的相关个股有国药控股、京东健康、阿里健康,振幅分别为5.06%、2.78%、1.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240826093120ab5fa48b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240826093120ab5fa48b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0640798160.USD","BK1500","BK1197","BK1515","01099","LU1115378108.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":-0.0949},{"period":"1month","weight":-0.0369},{"period":"3month","weight":-0.117},{"period":"6month","weight":-0.1552},{"period":"1year","weight":-0.1849},{"period":"ytd","weight":-0.0932}],"compareEarnings":[{"period":"1week","weight":0.0208},{"period":"1month","weight":0.0501},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0826},{"period":"1year","weight":-0.0141},{"period":"ytd","weight":0.0485}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品及医疗器械分销业务的中国公司。该公司通过四个部门运营业务。医药分销部门向医院、其他分销商、零售药店及诊所等客户分销医药制品。医疗器械业务部门向客户分销医疗器械,并提供安装和维修服务。医药零售业务部门经营医药连锁店。其他业务部门分销实验室用品、制造及分销化学试剂、生产及销售医药制品。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.002673},{"month":2,"riseRate":0.6,"avgChangeRate":0.035653},{"month":3,"riseRate":0.533333,"avgChangeRate":0.016153},{"month":4,"riseRate":0.4,"avgChangeRate":0.023272},{"month":5,"riseRate":0.6,"avgChangeRate":-0.007238},{"month":6,"riseRate":0.4,"avgChangeRate":-0.006667},{"month":7,"riseRate":0.466667,"avgChangeRate":-0.01785},{"month":8,"riseRate":0.466667,"avgChangeRate":0.012},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.021825},{"month":10,"riseRate":0.666667,"avgChangeRate":0.048869},{"month":11,"riseRate":0.4,"avgChangeRate":-0.013868},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.005961}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}